{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '5.0 STUDY POPULATION', 'The subjects will be male and/or female subjects, 9 years of age and older, with moderate to severe', 'CI genetically confirmed to be of either the ARCI-LI or RXLI subtypes according to', 'protocol-specified definitions.', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as', 'protocol waivers or exemptions, is not permitted.', '5.1', 'Inclusion Criteria', 'To enter the study, a subject must meet the following criteria:', '1. Subject is male or female, 9 years of age and older at Visit 2 (Baseline).', '2. Subject has provided written informed consent/assent. A subject under 18 years of age must', 'provide written informed assent and be accompanied by the parent or legal guardian at the time', 'of consent/assent signing. The parent or legal guardian must provide informed consent for the', 'subject. If a subject becomes 18 years of age during the study, the subject must provide written', 'informed consent at that time to continue study participation.', '3. Females must be postmenopausal (defined as amenorrhea greater than 12 consecutive months', 'in women 50 years of age and older), surgically sterile (hysterectomy, bilateral', 'salpingectomy, or bilateral oophorectomy), or use acceptable forms of birth control. Women', 'of childbearing potential (WOCBP) must have a negative urine pregnancy test (UPT) at', 'Visit 2 (Baseline) (UPTs must have a minimum sensitivity to detect 25 mIU beta-human', 'chorionic gonadotropin [\u00df-hCG]/mL). Methods of acceptable contraception are further', 'defined in Appendix 6. Female subjects who become sexually active or begin to have', 'relations with a partner during the study must agree to use 2 forms of birth control for', '30 days prior to having relations and to continue such forms for the duration of the study.', '4.', 'Subject has clinical diagnosis of CI and has a genetic confirmation of either ARCI-LI (eg,', 'transglutaminase 1-deficient) or RXLI (eg, deletion of steroid sulfatase gene) subtypes of CI.', 'For ARCI-LI subjects, enrollment is not limited to Transglutaminase 1 mutations. Other', 'genetically confirmed ARCI-LI mutations can potentially be enrolled as long as the phenotype', 'is consistent with ARCI-LI and the other inclusion criteria are met, as determined by the', 'Investigator. Congenital Ichthyosis XomeDxSlice will be used to diagnose both RXLI and', 'ARCI-LI. GeneDx tests detect transglutaminase mutations in the TGM1 gene, X-linked', 'recessive steroid sulfatase mutations in the STS gene, and additionally analyzes 47 other genes', 'linked to CI. This is a multi-gene panel testing so that all known causes of CI can be', 'confirmed/ruled-out since there is phenotypic overlap between the subtypes (including STS).', 'The tests are considered Laboratory Developed Tests (LDTs) and are thus regulated per US', 'regulations 42 CFR 493 and the laboratory is accredited by the College of American', 'Pathologists.', '24']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '5. The amount of CI affected skin in the Treatment Area at Baseline will be between a minimum', 'of 10% and maximum of 90% of the total BSA (1% BSA is approximately equal to the surface', \"area of the subject's palm and fingers, with the fingers extended yet grouped together, creating\", 'a flat oval-like surface area).', \"6. Subject's designated VIIS assessment areas MUST:\", 'Include any of the 4 VIIS assessment areas that have some CI disease involving: (a) the', 'upper back from the posterior axillary fold to the other encompassing the T1-T10, (b) the', 'upper arm (excluding elbows), left or right, (c) the shin/lower leg (the portion below the', 'proximal aspect of the knee cap), left or right, and (d) dorsal foot (left or right); AND', 'At least 2 of the 4 VIIS assessment areas MUST have a scaling score of 3 or more.', '7.', 'Subject and parent/guardian (if applicable) are willing and able to apply the study treatment(s)', 'as directed, comply with study instructions, and commit to all follow-up visits for the duration', 'of the study.', \"8. Subject, in the Investigator's opinion, is in good general health and free of any disease state or\", 'physical condition that might impair evaluation of the Treatment/Assessment Areas or exposes', 'the subject to an unacceptable risk by study participation.', '5.2', 'Exclusion Criteria', 'A subject is ineligible to enter the study if he/she meets 1 or more of the following criteria:', '1. Subject is pregnant, lactating, or is planning to become pregnant during the study.', '2. Subject has inflammatory skin diseases that confound the interpretation of results (eg, atopic', 'dermatitis) unrelated to ichthyosis.', '3.', 'Subject has previously failed on topical/oral retinoid therapy for treatment of CI.', '4. Subject, in the Treatment/Assessment Areas, has used: (a) topical retinoids or any other topical', 'prescription or over-the-counter therapies (except emollients, keratolytics, and topical steroids', '- see below), that are intended for, or that in the opinion of the Investigator, may improve CI', 'within 2 weeks of Visit 2 (Baseline), or (b) keratolytics or topical corticosteroids within 5 days', 'prior to Visit 2 (Baseline).', '5.', 'Subject has used any topical products in the Treatment/Assessment Areas, including bland', 'emollients, on Visit 2 (Baseline) prior to randomization.', '6. Subject has used ultraviolet (UV) treatment within 4 weeks prior to Visit 2 (Baseline).', '7.', \"Subject has undergone systemic therapies using vitamin A supplements or St. John's Wort\", 'within 4 weeks prior to Visit 2 (Baseline). Note: Use of a multivitamin including Vitamin A', 'is not exclusionary provided it is taken as directed on the packaging.', '8. Subject has used systemic retinoids within 12 weeks of Visit 2 (Baseline) or any other systemic', 'therapies that are intended for or may improve CI within 4 weeks of Visit 2 (Baseline).', '9. Subject is immunosuppressed (eg, human immunodeficiency virus, systemic malignancy, graft', 'host disease) or receives systemic immunotherapy.', '25']\n\n###\n\n", "completion": "END"}